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Background
Allergic rhinitis (AR) is one of uncontrollable inflamma-
tion diseases by a corticosteroid administration. Thus an
ideal AR animal model had been required in this
research field in order to develop a new effective
remedy. We report our establishment of the novel AR
animal model resistant to nasal corticosteroid.
Methods
BALB/c mice were sensitized by intraperitoneal injection
of ovalbumin (OVA) /ALUM. Two weeks after the sen-
sitization, the mice were administrated OVA intranasally
for five times a week (One-week-challenge arm), or five
days in the first week followed by three times a week for
every two days from the second to the fifth week (Five-
week-challenge arm). In the both arms, the day before
the first challenge, the mice were randomly divided into
four groups (n=8): negative control (NC), vehicle control
(VC), mometasone furoate (MF), and dexamethasone
(DEX). For the NC groups, sensitized mice were intra-
nasally treated with saline instead of OVA. In the MF
groups, 5 μg/10 μL of MF was administrated intranasally
30 minutes before the last OVA challenge. In the DEX
groups, 1 mg/kg of DEX was administrated orally 1
hour before the last OVA challenge. The nasal conges-
tion in early phase and late phase responses were mea-
sured by two-chambered, double-flow plethysmograph
system as specific air way resistance (sRAW) 10 minutes
and 3 hours after the last OVA challenge, respectively.
The mice were sacrificed by CO2 gas inhalation and the
nasal paraffin sections were made for histological
evaluation.
Results
In the One-week-challenge arm, the sRAW in MF and
DEX group were lower than VC group both in the early
(inhibition rates: MF 73%, DEX 94%) and the late phase
responses (MF 76%, DEX 84% inhibition). In the Five-
weeks-challenge arm, MF and DEX reduced the nasal
congestion in the early phase (MF 42%, DEX 58% inhibi-
tion), however, the inhibition rate of the late phase was
significantly decreased in the MF group (MF 28%, DEX
50% inhibition). The epithelial hyperplasia and the
inflammatory cells infiltration were observed in the nasal
mucosa, and these grades were more remarkable for
Five-week-challenge arm than One-week-challenge arm.
Conclusions
After five weeks OVA challenge, the nasal congestion
remained partially even after the nasal corticosteroid
treatment. This repeated OVA administration method
would provide a quite useful novel disease model to elu-
cidate the mechanisms of nasal steroid-resistant-AR and
develop a new remedy.
Published: 8 April 2015
doi:10.1186/1939-4551-8-S1-A30
Cite this article as: Izumi et al.: Novel mouse model of steroid-resistant
allergic rhinitis by repeated intranasal administration of OVA. World
Allergy Organization Journal 2015 8(Suppl 1):A30.
Otsuka Pharmaceutical Co., Ltd, Japan
Izumi et al. World Allergy Organization Journal 2015, 8(Suppl 1):A30
http://www.waojournal.org/content/8/S1/A30
© 2015 Izumi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
